Steady innovation and resilient profitability continue to underpin this healthcare leader’s dividend profile. With a low beta of 0.70 and a healthy 7% three-year dividend CAGR, the stock exemplifies what the Best Dividend Stocks Portfolio values most—predictability, growth, and balance. The company’s diversified product lineup across devices, diagnostics, and nutrition ensures steady cash flows, while disciplined capital management maintains attractive shareholder returns despite sector headwinds.
Reaffirmed in our portfolio this quarter, this healthcare stalwart demonstrates how durable earnings, stable leverage, and consistent dividend growth can coexist with moderate yield levels. Innovation-driven gains in medical devices continue to offset diagnostic declines, reflecting the benefits of its global diversification and strong execution in core therapeutic categories.
Readers interested in uncovering the full details behind our increased allocation and understanding how this quality dividend stock continues to outshine peers in consistency and capital discipline should explore the complete analysis in the full article.
